BBOT - BridgeBio Oncology Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$22.00
LOW:
$15.00
MEDIAN:
$20.00
CONSENSUS:
$19.00
UPSIDE:
283.84%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | |||||
| R&D Expenses | 121.2 | 73.1 | 56.3 | 0 | 0 |
| SG&A Expenses | 24.6 | 7.8 | 8.5 | 0.0 | 0.0 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 145.8 | 80.9 | 64.8 | 0.0 | 0.0 |
| Operating Income | |||||
| Operating Income | (145.8) | (80.9) | (64.8) | (0.0) | (0.0) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 11.3 | 6.4 | 0.1 | 0 | 0 |
| Profitability | |||||
| EBITDA | (145.2) | (80.7) | (64.7) | (0.0) | (0.0) |
| EBIT | (145.8) | (80.9) | (64.8) | (0.0) | (0.0) |
| Income Before Tax | (134.0) | (74.3) | (64.7) | (0.0) | (0.0) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (134.0) | (74.3) | (64.7) | (0.0) | (0.0) |
| Per Share Data | |||||
| EPS (Basic) | -4.30 | -5756.41 | -0.00 | – | -0.00 |
| EPS (Diluted) | -4.30 | -5756.41 | -3.16 | -0.00 | -0.00 |
| Shares Outstanding | 31.1 | 0.0 | 20.5 | 20.5 | 20.5 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Current Assets | |||||
| Cash & Cash Equivalents | 373.7 | 1.7 | 0 | 0 | 0 |
| Short-Term Investments | 51.8 | 0 | 0 | 0 | 0 |
| Net Receivables | 0.4 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | (0.4) | 0 | 0 | 0 | 0 |
| Total Current Assets | 425.5 | 1.9 | 0 | 0 | 0 |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0.1 | 192.4 | 0 | 0 | 0 |
| Other Non-Current Assets | 22.8 | 0.0 | 0.3 | 0.1 | 0.1 |
| Total Non-Current Assets | 22.9 | 192.5 | 0.3 | 0.1 | 0.1 |
| Total Assets | 448.4 | 194.4 | 0.3 | 0.1 | 0.1 |
| Current Liabilities | |||||
| Account Payables | 1.4 | 0 | 0 | 0 | 0 |
| Short-Term Debt | 0 | 0 | 0.1 | 0.0 | 0.0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.7 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 35.0 | 0.2 | 0.4 | 0.2 | 0.2 |
| Non-Current Liabilities | |||||
| Long-Term Debt | 2.2 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 5.5 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 2.2 | 5.5 | 0 | 0 | 0 |
| Total Liabilities | 37.3 | 5.7 | 0.4 | 0.2 | 0.2 |
| Stockholders' Equity | |||||
| Common Stock | 0.0 | 192.4 | 0.0 | 0.0 | 0.0 |
| Retained Earnings | (356.6) | (3.7) | (0.1) | (0.0) | (0.0) |
| Accumulated Other Comprehensive Income | 0.0 | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 411.1 | 188.7 | (0.1) | (0.0) | (0.0) |
| Total Liabilities & Equity | 448.4 | 194.4 | 0.3 | 0.1 | 0.1 |
| Debt Metrics | |||||
| Total Debt | 2.8 | 0 | 0.1 | 0.0 | 0.0 |
| Net Debt | (370.9) | (1.7) | 0.1 | 0.0 | 0.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | (134.0) | 7.6 | (64.7) | (0.0) | (0.0) |
| Depreciation & Amortization | 0.6 | 0 | 0.1 | 0 | 0 |
| Stock-Based Compensation | 5.9 | 0.3 | 16.5 | 0 | 0 |
| Change in Working Capital | 6.4 | (0.1) | (3.9) | 0 | 0 |
| Other Non-Cash Items | 7.2 | (8.5) | 0 | 0.0 | 0.0 |
| Operating Cash Flow | (113.9) | (0.8) | (52.1) | 0 | 0 |
| Investing Activities | |||||
| Capital Expenditure | (0.6) | 0 | (0.4) | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (83.9) | (184) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 157.9 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (2.4) | 0 | 0 |
| Investing Cash Flow | 73.3 | (184) | (2.8) | 0 | 0 |
| Financing Activities | |||||
| Net Debt Issuance | 0 | (0.2) | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.3) | (0.6) | 0 | 0 | 0 |
| Financing Cash Flow | 383.4 | 186.5 | 55.1 | 0 | 0 |
| Cash Position | |||||
| Net Change in Cash | 342.8 | 1.7 | 0.2 | 0 | 0 |
| Cash at Beginning | 31.0 | 0 | 0.0 | 0 | 0 |
| Cash at End | 373.8 | 1.7 | 0.2 | 0 | 0 |
| Free Cash Flow | (114.5) | (0.8) | (52.5) | 0 | 0 |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | (145.8) | (80.9) | (64.8) | (0.0) | (0.0) |
| Net Income | (134.0) | (74.3) | (64.7) | (0.0) | (0.0) |
| EPS (Diluted) | -4.30 | -5756.41 | -3.16 | -0.00 | -0.00 |
| Balance Sheet | |||||
| Cash & Equivalents | 373.7 | 1.7 | 0 | 0 | 0 |
| Total Assets | 448.4 | 194.4 | 0.3 | 0.1 | 0.1 |
| Total Debt | 2.8 | 0 | 0.1 | 0.0 | 0.0 |
| Stockholders' Equity | 411.1 | 188.7 | (0.1) | (0.0) | (0.0) |
| Cash Flow | |||||
| Operating Cash Flow | (113.9) | (0.8) | (52.1) | 0 | 0 |
| Capital Expenditure | (0.6) | 0 | (0.4) | 0 | 0 |
| Free Cash Flow | (114.5) | (0.8) | (52.5) | 0 | 0 |